Syndrome News and Research

RSS

EMA approves TWYNSTA therapy that reduces BP in hypertensive patients

Boehringer Ingelheim announced today that the European Commission confirmed the positive opinion of the European Medicines Agency (EMA) approving TWYNSTA. TWYNSTA is indicated for the treatment of hypertension in adults whose blood pressure is not adequately controlled on amlodipine or as replacement therapy in adult patients receiving telmisartan and amlodipine from separate tablets containing the same component doses.

12 Oct 2010

Albireo reports positive results from A3309 Phase IIb study in chronic idiopathic constipation

Albireo today announced positive top-line results from a Phase IIb study in chronic idiopathic constipation (CIC) assessing efficacy and safety of three different dose levels (5, 10 and 15 mg orally once a day) of the investigational drug A3309 during an eight week trial. Analyses of the data show clinically meaningful and statistically significant improvement for patients treated with A3309 compared to placebo-treated patients.

12 Oct 2010

Insulin resistance increases risk of stroke in non-diabetic patients

Insulin resistance, a condition in which insulin produced by the body becomes less effective in reducing blood glucose levels, appears to be associated with an increased risk of stroke in individuals without diabetes, according to a report in the October issue of Archives of Neurology, one of the JAMA/Archives journals.

12 Oct 2010

Research reveals new details about health benefits of fish-oil

Some of America's most popular fish salmon and albacore tuna, for example are rich in healthful natural compounds known as omega-3 fatty acids. Ongoing studies by U.S. Department of Agriculture (USDA) chemist Darshan S. Kelley and co-investigators are helping uncover new details about how these fish-oil components help protect us from chronic diseases.

12 Oct 2010

Attorney Keith Jensen announces $3.78 million settlement with Pfizer on TEN case

Attorney Keith Jensen of the Fort Worth, Texas-based law firm of Jensen, Belew & Gonzalez is announcing a $3.78 million settlement with pharmaceutical manufacturer Pfizer Inc. on behalf of the family of a nine-year-old New York girl who died in June 2004 as the result of a drug-induced disease known as Stevens Johnson Syndrome, which caused all of her skin to peel off.

11 Oct 2010

Genentech initiates GDC-0449 Phase II clinical trial in BCC patients

Curis, Inc. a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that its collaborator Genentech, a member of the Roche Group, has initiated a Phase II clinical trial of GDC-0449, an orally-administered small molecule Hedgehog Pathway Inhibitor, as a single-agent therapy for patients with operable basal cell carcinoma (BCC).

11 Oct 2010

AVEO presents tivozanib Phase 2 study results at ESMO Congress

AVEO Pharmaceuticals, Inc. a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that previously reported results from its Phase 2 study evaluating tivozanib for the treatment of advanced renal cell carcinoma (RCC) were presented at the 35th European Society for Medical Oncology (ESMO) Congress in Milan, Italy.

11 Oct 2010

ACT Biotech reports positive interim data from Telatinib Phase 2 trial for advanced gastric cancer

ACT Biotech Inc., a privately held biotechnology company based in San Francisco, California, today announced positive interim data from a Phase 2 trial of the Company's lead oral kinase inhibitor, Telatinib, for the first-line treatment of patients with advanced gastric cancer. This proof-of-concept, multi-center, open label trial was designed to test the efficacy and safety of full-dose Telatinib, administered continuously, as a first-line treatment in combination with a standard regimen of capecitabine and cisplatin in US and European patients.

11 Oct 2010

Afinitor-Sandostatin LAR Depot combination extends median PFS in patients with advanced carcinoid tumors

A Novartis Pharmaceuticals Corporation Phase III study of Afinitor® (everolimus) tablets in combination with Sandostatin® LAR Depot (octreotide acetate for injectable suspension) extended median progression-free survival (PFS), or time without tumor growth, in patients with advanced carcinoid tumors compared to taking octreotide LAR alone.

11 Oct 2010

CDC, national leaders issue recommendations to standardize testosterone tests

The use of testosterone assays for patient care and research is on the rise as new research links testosterone to a variety of diseases and conditions. Although the assays are heavily used, discrepancies and inaccuracies in measurements resulting from the various assays are widespread.

11 Oct 2010

Researchers investigate ways to minimize risk of multiple pregnancies

The complication rate during pregnancy with twins is about 40%. Women with multiple pregnancies often develop pre-eclampsia, gestational diabetes, and hemorrhages during the term of their pregnancy. Joachim W Dudenhausen from the Charité Berlin University Medicine and Rolf F Maier from Magdeburg University Medical Center, investigate which risks can be minimized by close monitoring in multiple pregnancies.

11 Oct 2010

UH researchers receive grant to develop Blue Scale device to track heart failure

As more and more medical care is provided in the home, health specialists say it is critical for people to be able to monitor themselves and make informed judgments about their health. A group of researchers in the Abramson Center for the Future of Health at the University of Houston (UH) received a $250,000 pre-seed grant from the Texas Emerging Technology Fund (ETF) for a system that assesses cardiac function in the home and alerts the user to the need for intervention.

11 Oct 2010

Abbott to withdraw Meridia medicine from the U.S. market

Abbott will voluntarily withdraw Meridia (sibutramine) from the U.S. market at the request of the U.S. Food and Drug Administration (FDA).

11 Oct 2010

Discovery can lead to new approach for treating MS in early stages

A deficiency in one of the immune system's enzymes affects the severity of autoimmune diseases such as MS, and explains why the course of these diseases can vary so much. New findings give an insight into how this enzyme deficiency can be diagnosed, and could lead to new medicines, reveals a thesis from the Sahlgrenska Academy.

11 Oct 2010

Presbyterian Hospital collaborates with New York Center for Autism to establish Institute for Brain Development

NewYork-Presbyterian Hospital, along with its affiliated medical schools Columbia University College of Physicians and Surgeons and Weill Cornell Medical College, announced its collaboration with the New York Center for Autism to establish the Institute for Brain Development, a comprehensive, state-of-the-art institute dedicated to addressing the pressing clinical needs of individuals living with autism spectrum disorders and other developmental disorders of the brain, across their lifespan.

8 Oct 2010

Clinical study data on Natural S-equol supplement presented at NAMS Annual Meeting

Four clinical studies that add to the evidence about the use of a new nutritional supplement containing the whole soy germ-based ingredient Natural S-equol to improve health were presented at the North American Menopause Society (NAMS) Annual Meeting.

8 Oct 2010

Phase 3 study of D-tagatose in Type 2 diabetes shows significant reduction in HbA1c levels

Spherix Incorporated, an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis; and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that its Phase 3 study of D-tagatose as a monotherapy in Type 2 diabetes showed a statistically significant (p<0.05) reduction in HbA1c levels of 0.4% at 10 months in relatively healthy people with diabetes

8 Oct 2010

Researchers unveil clues to combat enteritis in humans

The bacterium Campylobacter jejuni is a major cause of food poisoning in humans. It is normally transmitted from contaminted chicken meat, as it is frequently found in the intestines of chickens, where it apparently does not result in any symptoms. Researchers at the University of Veterinary Medicine, Vienna have now solved the puzzle, showing that Campylobacter can survive ambient oxygen levels thanks to the presence of other bacteria, species of Pseudomonas.

7 Oct 2010

Study shows radioembolisation with TheraSphere effective for primary liver cancer

MDS Nordion, a leading provider of products and services to the global health science market, today announced that the first large European study using Yttrium-90 (Y-90) glass microspheres has been published on the use of TheraSphere, an innovative radioembolisation therapy for the localised treatment of patients with advanced hepatocellular carcinoma (HCC) or primary liver cancer.

7 Oct 2010

Privigen IVIg therapy effective for primary, secondary immunodeficiencies: Study

Privigen, the first and only 10% liquid intravenous immunoglobulin (IVIg) therapy stabilized with proline, is effective and well tolerated in patients with several primary and secondary immunodeficiencies, according to data presented today at the XIVth Meeting of the European Society for Immunodeficiencies. Results also demonstrate that Privigen offers significant protection against infection.

7 Oct 2010

Syndrome News and Research

EMA approves TWYNSTA therapy that reduces BP in hypertensive patients

Albireo reports positive results from A3309 Phase IIb study in chronic idiopathic constipation

Insulin resistance increases risk of stroke in non-diabetic patients

Research reveals new details about health benefits of fish-oil

Attorney Keith Jensen announces $3.78 million settlement with Pfizer on TEN case

Genentech initiates GDC-0449 Phase II clinical trial in BCC patients

AVEO presents tivozanib Phase 2 study results at ESMO Congress

ACT Biotech reports positive interim data from Telatinib Phase 2 trial for advanced gastric cancer

Afinitor-Sandostatin LAR Depot combination extends median PFS in patients with advanced carcinoid tumors

CDC, national leaders issue recommendations to standardize testosterone tests

Researchers investigate ways to minimize risk of multiple pregnancies

UH researchers receive grant to develop Blue Scale device to track heart failure

Abbott to withdraw Meridia medicine from the U.S. market

Discovery can lead to new approach for treating MS in early stages

Presbyterian Hospital collaborates with New York Center for Autism to establish Institute for Brain Development

Clinical study data on Natural S-equol supplement presented at NAMS Annual Meeting

Phase 3 study of D-tagatose in Type 2 diabetes shows significant reduction in HbA1c levels

Researchers unveil clues to combat enteritis in humans

Study shows radioembolisation with TheraSphere effective for primary liver cancer

Privigen IVIg therapy effective for primary, secondary immunodeficiencies: Study

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News